GENSCRIPT-BIOTECH
16.12.2021 09:02:13 CET | Business Wire | Press release
GenScript Biotech Corp ., a global biotechnology group, announced today that it has expanded operations in the United Kingdom with new offices and a fully functional logistics center in Oxford. The facility supports U.K. customers with fast delivery of high-quality products and services for expediting research, as well as technical support.
"The U.K. biosciences sector is one of the industry's leading innovation hubs, particularly in the cell and gene therapy fields," said Aaron Qian, president of the European Division at GenScript. "We are excited to support our regional customers as they scale up from R&D through GMP, and we look forward to becoming a more active member of the U.K. biosciences community."
The facility features certified cold chain storage and transportation for receipt and delivery of samples and products with rapid turnaround time. The trained logistics team will also help with customs clearance after Brexit. Additionally, the new GenScript office will house sales and account managers specializing in field technical support. The office will employ approximately 50 people, with plans to double over the next two years.
GenScript maintains sales, R&D and manufacturing operations in the U.S., Asia and Europe. The company has over 100,000 customers in 100+ countries.
About GenScript Biotech Corporation
GenScript Biotech Corporation (Stock Code: 1548.HK) is a global biotechnology group. Based on its leading gene synthesis technology, GenScript has developed four major platforms, including the global cell therapy platform, the biologics contract development and manufacturing organization (CDMO) platform, the contract research organization (CRO) platform and the industrial synthesis product platform.
GenScript was founded in New Jersey, US in 2002 and listed on the Hong Kong Stock Exchange in 2015. GenScript's business operation spans over 100 countries and regions worldwide, with legal entities located in the U.S., Mainland China, Hong Kong, Japan, Singapore, Netherlands and Ireland. GenScript has provided premium, convenient, and reliable products and services for over 100,000 customers.
GenScript has a number of intellectual property rights and technical secrets, including more than 100 patents and over 270 patent applications. As of December 31-st, 2020, GenScript's products and services have been cited by 52,500 peer-reviewed journal articles worldwide.
For more information visit www.genscript.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211215006193/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Gurobi’s Decision Intelligence Summit Comes to Prague13.10.2026 09:00:00 CEST | Press release
The Gurobi Summit EMEA returns October 13–14 to showcase why optimization is the AI that drives trusted decisions. Gurobi Optimization, LLC, the leader in decision intelligence technology, today unveiled the 2026 Gurobi Decision Intelligence Summit (“Gurobi Summit”) EMEA, taking place October 13–14 in Prague. Following the U.S. version of the event, which took place September 22-23 in Las Vegas, attendees in the EMEA region will gather at the Fantova Budova for two days of innovative use case presentations, in-depth trainings, and expert-led panels. Sessions will highlight how optimization is the most suitable form of AI for delivering actionable, defensible decisions, and how generative AI can break down barriers to entry and help more users apply optimization’s full potential. This year’s presentations will include speakers from ALDI, Dutch Railways, Ryanair Labs, SAP, Skydance, and more. Several of Gurobi’s partners will also be present to showcase their solutions and expertise. In
YouHodler Italy Authorised by CONSOB as a Crypto-Asset Service Provider Under MiCA13.10.2026 09:00:00 CEST | Press release
Authorisation covers custody, exchange of crypto-assets for funds and for other crypto-assets, execution of orders and transfer services YouHodler Italy S.r.l., announces that CONSOB, after hearing the Bank of Italy, has authorised it as a crypto-asset service provider (CASP) under Regulation (EU) 2023/1114 (MiCA) and Legislative Decree 129/2024, by resolution no. 24156 of 8 October 2026. The authorisation covers five services: custody and administration of crypto-assets on behalf of clients; exchange of crypto-assets for funds; exchange of crypto-assets for other crypto-assets; execution of orders on behalf of clients; and transfer services for crypto-assets on behalf of clients. With the authorisation, YouHodler Italy serves clients in Italy as a supervised firm under MiCA's client protections: segregation of client crypto-assets, governance and security requirements, pre-contractual information and complaints handling. The company plans to extend its services to all 27 EU Member Sta
Manhattan Wins Kesko Mandate as Nordic Retail Giant Bets on Cloud-Native, AI-Driven Warehousing13.10.2026 09:00:00 CEST | Press release
The race to modernise Europe's grocery supply chains has entered a new phase, with Finnish retail group Kesko selecting ActiveWarehouse™ from leading supply chain and omnichannel commerce solutions provider Manhattan Associates Inc. (NASDAQ: MANH). The Nordic retail giant is replacing its grocery trade legacy warehouse management system with the industry’s leading, cloud-native warehouse management solution, including agentic AI capabilities delivered through ActiveAgents™ and Agent Foundry. For Finland’s second largest grocery brand, and one of the biggest in Northern Europe, the investment reflects the growing strategic importance of operational agility, as digital and physical retail become increasingly interconnected and a broader shift taking place across retail logistics more generally. The scale of Kesko’s grocery trade makes the project noteworthy in Finnish and European retail. In 2025, the division’s net sales amounted to EUR 6.5 billion, and its comparable operating profit w
Horizon3 Promotes Keith Poyser to General Manager, EMEA Following More Than 260% Regional Revenue Growth13.10.2026 09:00:00 CEST | Press release
Poyser built the EMEA team from eight to more than 110 employees and will lead the company’s next phase of expansion across the region. Horizon3 today announced the promotion of Keith Poyser to General Manager, EMEA. Previously Vice President, EMEA, Poyser will oversee the company’s next phase of growth and expansion across Europe, the Middle East and Africa. His promotion follows more than 260% regional revenue growth in the last fiscal year and the opening of Horizon3’s EMEA headquarters in Amsterdam. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261013365926/en/ Keith Poyser promoted to General Manager, EMEA following more than 260% regional revenue growth Since joining Horizon3 in September 2024, Poyser has recruited experienced talent and established a regional leadership bench, growing the EMEA team from eight to more than 110 employees. He has built a culture of trust, collaboration and accountability to support the
New Galderma Research Reveals More Than Half of Women Mistake Menopause-Related Skin Changes for Signs of Ageing13.10.2026 07:00:00 CEST | Press release
New clinical data identify optimized injectable aesthetics treatment protocol for menopause-induced skin changes 56% of women have experienced ‘The Menopausal Skin Misread’, admitting they first put menopause-related skin changes down to ageing, while fewer than a third (29%) recognized menopause as the cause1 A significant knowledge gap remains: one in two women are unaware that hormonal changes during perimenopause and menopause can affect the skin, and 82% agree that better understanding the difference between menopause-related skin changes and general ageing would help them feel more informed and in control of their skincare decisions1 New data from an investigator-initiated trial (IIT) led by Dr. Andreas Nikolis and supported by Galderma, demonstrated that a sequenced treatment approach using Restylane Skinboosters followed by Sculptra delivered significant improvements in skin hydration and remodeling across the face and décolletage in menopausal women, highlighting the value of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom